Pan-India multidisciplinary program aims to improve coordinated care for patients with chronic kidney disease and heart failure
Both companies will promote, market and distribute Sodium Zirconium Cyclosilicate in India under different brand names
Experts urge early detection & better access to care
Finerenone is the first mineralocorticoid receptor (MR) antagonist to demonstrate definitive cardiovascular benefits in a Phase III study in patients with heart failure (HF) with a left ventricular ejection fraction (LVEF) of ?40%
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
